Press Releases

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

December 9, 2024

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

November 14, 2024

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

November 7, 2024

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

October 25, 2024

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

September 16, 2024

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 4, 2024

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

September 3, 2024

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

August 14, 2024

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

August 7, 2024

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

June 13, 2024